John Dobak

10XBio LLC is an American biotechnology company that specializes in finding new uses for existing therapies and technologies. By leveraging known mechanisms of action and building on existing safety profiles, the private company is able to streamline the development and regulatory process. The company's most advanced asset, 10xb101, is a pharmaceutical product that addresses unmet needs in aesthetic medicine. The company's focus on repurposing existing therapies and technologies allows for accelerated development and a more efficient regulatory process.

DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use.

CryoCor, Inc. provided medical technology services. It developed and manufactured a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The firm's product the CryoCor Cardiac Cryoablation System, was designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The company was founded in 2000 and was headquartered in San Diego, CA.